Method of treating an inflammatory condition by administering toll-like 3 receptor antagonists

Patent metadata

Field	Value
Publication number	US-9522957-B2
Application number	US-201313973187-A
Country	US
Kind code	B2
Filing date	Aug 22, 2013
Priority date	Oct 31, 2008
Publication date	Dec 20, 2016
Grant date	Dec 20, 2016

Abstract

Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.

First claim

The invention claimed is:

1. A method of treating an inflammatory condition comprising administering a therapeutically effective amount of an isolated antibody or fragment thereof to a patient in need thereof for a time sufficient to treat or prevent the inflammatory condition, wherein the antibody binds toll-like receptor 3 (TLR3) amino acid residues K416, K418, L440, N441, E442, Y465, N466, K467, Y468, R488, R489, A491, K493, N515, N516, N517, H539, N541, S571, L595, and K619 of SEQ ID NO: 2.

2. A method of treating an inflammatory condition comprising administering a therapeutically effective amount of an isolated antibody or fragment thereof to a patient in need thereof for a time sufficient to treat or prevent the inflammatory condition, wherein the isolated antibody comprises a heavy chain variable region and a light chain variable region or fragment thereof and the isolated antibody heavy chain variable region Chothia residues W33, F50, D52, D54, Y56, N58, P61, E95, Y97, Y100, and D100b and the isolated antibody light chain variable region Chothia residues Q27, Y32, N92, T93, L94, and S95 bind toll-like receptor 3 (TLR3) that has the amino acid sequence shown in SEQ ID NO: 2.

3. The method of claim 1 or 2 , wherein the inflammatory condition is an inflammatory pulmonary condition, inflammatory bowel disease, autoimmune disease, systemic inflammatory condition, or rheumatoid arthritis.

4. The method of claim 3 , wherein the inflammatory pulmonary condition is asthma, chronic obstructive pulmonary disease (COPD), airway hyperresponsiveness, or is induced by Nontypeable Haemophilus influenza.

5. The method of claim 3 , wherein the systemic inflammatory condition is cytokine storm or hypercytokinemia, systemic inflammatory response syndrome (SIRS), graft versus host disease (GVHD), acute respiratory distress syndrome (ARDS), severe acute respiratory distress syndrome (SARS), catastrophic anti-phospholipid syndrome, severe viral infections, influenza, pneumonia, shock, or sepsis.

6. The method of claim 5 , wherein the inflammatory condition is associated with gastrointestinal ulceration.

7. The method of claim 6 , wherein the gastrointestinal ulceration is associated with infectious colitis, ischemic colitis, collagenous or lymphocytic colitis or necrotizing enterocolitis.

Assignees

• Janssen Biotech Inc

Inventors

• Cunningham Mark
• Feng Yiqing
• Heeringa Katharine
• Luo Jinquan
• Rauchenberger Robert
• Rutz Mark
• San Mateo Lani
• Sarisky Robert
• Sweet Raymond
• Teng Fang
• Teplyakov Alexey
• Wu Sheng-Jiun

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title